Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report) and ...

Hundreds of lawsuits allege that insulin manufacturers and pharmacy benefit managers colluded to raise prices. The ...

Novo Nordisk and Sanofi were among companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs ...

Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, ...

Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

Jefferies analyst Benjamin Jackson CFA maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Sanofi and Eli Lilly. We raised our fair value estimate for Novo Nordisk to DKK 640 per share from DKK 600 following a solid management outlook for 2025 that likely reflects stronger growth in GLP ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

March 4, 2025 South African watchdog probes Novo Nordisk and Sanofi over insulin South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti ...